Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

IRIS-RA

- PMLiVE

Novartis’ ianalumab shows promise in phase 3 Sjögren’s syndrome studies

The systemic autoimmune disease affects approximately 0.6% of the UK’s adult population

- PMLiVE

Novartis and Matchpoint enter inflammatory disease partnership worth $1bn

The companies will focus on inflammatory diseases that have been historically difficult to treat

- PMLiVE

Johnson & Johnson’s Imaavy granted FDA approval for rare autoimmune disease gMG

Myasthenia gravis affects an estimated 700,000 people worldwide

- PMLiVE

Novartis gains rights to Kyorin’s chronic spontaneous urticaria candidate in deal worth $830m

The common skin condition affects approximately 40 million people worldwide

EU flag

EC approves Celltrion’s RoActemra biosimilar Avtozma for inflammatory diseases

The drug has been approved for rheumatoid arthritis, giant cell arteritis and other indications

- PMLiVE

Gilead and LEO enter inflammatory disease partnership worth up to $1.7bn

Targeting STAT6 has shown potential in treating a broad population of inflammatory disease patients

- PMLiVE

J&J’s nipocalimab granted FDA breakthrough designation for Sjögren’s disease

The chronic autoimmune disease affects approximately four million people globally

- PMLiVE

Sanofi/Regeneron’s Dupixent approved by EC for younger eosinophilic oesophagitis patients

Dupixent is now the first drug in the EU indicated for use in this patient population

- PMLiVE

J&J’s nipocalimab shows sustained disease control in adolescents with generalised myasthenia gravis

The severity of the rare autoimmune disease is heightened in paediatric patients

- PMLiVE

Merck and Mestag enter inflammatory disease partnership worth up to $1.9bn

The agreement will see Mestag use its platform designed to model the pathogenic role of fibroblasts

EU flag

EC approves Celltrion’s Stelara biosimilar SteQeyma for inflammatory diseases

The drug has been authorised for use in gastroenterology, dermatology and rheumatology indications

- PMLiVE

Johnson & Johnson shares positive phase 3 results for nipocalimab in myasthenia gravis

The rare autoimmune disease is estimated to affect around 700,000 people globally

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links